SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: TokyoMex who wrote (2919)3/27/1998 3:17:00 PM
From: Dan O.  Respond to of 34592
 
TM, try VD's model portfolio thread. Most of the bio guys check in there. Just ask for a simple answer <g>.

Dan O.



To: TokyoMex who wrote (2919)3/27/1998 4:50:00 PM
From: Bradpalm1  Respond to of 34592
 
Joe,

This small study involving SciClone's Zadaxin sounds very encouraging but the number of patients involved is very small. With these types of studies, one should wait for the results of larger clinical trials which will remove any doubt of therapeutic efficacy from random events alone. This shouldn't be difficult in the case of this agent given how prevalent liver cancer is overseas.

Bradpalm1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News